Rapport Therapeutics (RAPP) EBT (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly EBT of -$143.7 million for Q1 2026, up 98.82% year-over-year from -$72.3 million in Q1 2025, and up 2.65% quarter-over-quarter from -$147.6 million in Q4 2025.
Rapport Therapeutics (RAPP) EBT (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported EBT for 4 consecutive years, with -$143.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 98.82% year-over-year to -$143.7 million; the TTM figure through Mar 2026 stood at -$474.1 million (up 96.13% YoY), while the FY2025 annual figure was -$225.3 million, down 187.74% from the prior year.
- EBT advanced to -$143.7 million in Q1 2026 per RAPP's latest filing, from -$147.6 million in the prior quarter.
- Across five years, EBT topped out at -$6.4 million in Q2 2023 and bottomed at -$12.2 billion in Q1 2025.
- Historically, EBT has averaged -$1.1 billion across 4 years, with a median of -$19.1 million in 2024.
- Annual changes were most pronounced in 2025 — EBT sank 79809.42% — and 2026, when it surged 98.82%.
- Rapport Therapeutics' EBT stood at -$13.5 million in 2023, then sank by 47.86% to -$20.0 million in 2024, then plunged by 638.75% to -$147.6 million in 2025, then rose by 2.65% to -$143.7 million in 2026.
- Business Quant data shows RAPP's EBT at -$143.7 million in Q1 2026, -$147.6 million in Q4 2025, and -$139.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | -259.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -259.33 Mn |
| Mar 31, 2026 | -143.69 Mn |
| Dec 31, 2025 | -147.60 Mn |
| Sep 30, 2025 | -139.29 Mn |
| Jun 30, 2025 | -43.53 Mn |
| Mar 31, 2025 | -12.21 Bn |
| Dec 31, 2024 | -19.98 Mn |
| Sep 30, 2024 | -17.54 Mn |
| Jun 30, 2024 | -18.12 Mn |
| Mar 31, 2024 | -15.28 Mn |
| Dec 31, 2023 | -13.51 Mn |
| Sep 30, 2023 | -8.71 Mn |
| Jun 30, 2023 | -6.41 Mn |